Publications

1.Muller M, Broséus J, Guilloteau A, Wasse S, Thiéblemont C, Nancey S, et al. Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA. J Crohns Colitis. 2024 Apr 23;18(4):533–9.

2.Wasse SK, Mounier M, Assogba E, Rossi C, Adnet J, Gauthier S, et al. Factors Affecting Health-Related Quality of Life among Survivors of Non-Hodgkin Lymphoma: A Population-Based Study. Cancers (Basel). 2023 Jul 30;15(15):3885.

3.Atsou KM, Rachet B, Cornet E, Chretien ML, Rossi C, Remontet L, et al. Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France. Cancer Med. 2023 Apr;12(7):8911–23.

4.Boulin M, Cransac-Miet A, Maynadié M, Volot F, Creuzot-Garcher C, Eicher JC, et al. COVID-19 Lockdown in Patients with Chronic Diseases: A Cross-Sectional Study. Int J Environ Res Public Health. 2022 Mar 26;19(7):3957.

5.Mounier M, Romain G, Callanan M, Alla AD, Boussari O, Maynadié M, et al. Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM. J Clin Med. 2021 Apr 13;10(8):1657.

6.Greigert H, Mounier M, Arnould L, Creuzot-Garcher C, Ramon A, Martin L, et al. Heamatological malignancies in giant cell arteritis: a French population-based study. Rheumatology (Oxford). 2021 Nov 3;60(11):5408–12.

7.Le Guyader-Peyrou S, Orazio S, Dejardin O, Maynadié M, Troussard X, Monnereau A. Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? Haematologica. 2017 Mar;102(3):584–92.

8.Le Guyader-Peyrou S, Belot A, Maynadié M, Binder-Foucard F, Remontet L, Troussard X, et al. Cancer incidence in France over the 1980-2012 period: Hematological malignancies. Rev Epidemiol Sante Publique. 2016 Apr;64(2):103–12.

9.Rossi C, Jégu J, Mounier M, Dandoit M, Colonna M, Daubisse-Marliac L, et al. Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leuk Lymphoma. 2015;56(10):2876–82.

10.Penot A, Preux PM, Le Guyader S, Collignon A, Herry A, Dufour V, et al. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009. Leuk Lymphoma. 2015 Jun;56(6):1771–7.

11.Mounier M, Bossard N, Remontet L, Belot A, Minicozzi P, De Angelis R, et al. Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5). Lancet Haematol. 2015 Nov;2(11):e481-491.

12.Mounier M, Bossard N, Belot A, Remontet L, Iwaz J, Dandoit M, et al. Trends in excess mortality in follicular lymphoma at a population level. Eur J Haematol. 2015 Feb;94(2):120–9.

13.Dandoit M, Mounier M, Guy J, Petrella T, Girard S, Casasnovas RO, et al. The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry. Leuk Lymphoma. 2015 Apr;56(4):1050–7.

14.Dandoit M, Mounier M, Guy J, Petrella T, Girard S, Casasnovas RO, et al. The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry. Leuk Lymphoma. 2015 Apr;56(4):1050–7.

15.Leux C, Maynadié M, Troussard X, Cabrera Q, Herry A, Le Guyader-Peyrou S, et al. Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol. 2014 Aug;93(8):1327–33.

16.Monnereau A, Troussard X, Belot A, Guizard AV, Woronoff AS, Bara S, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer. 2013 May 15;132(10):2378–87.

17.Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013 Feb;98(2):230–8.

18.Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013 Jan;160(2):251–4.

19.Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012 Nov;48(17):3257–66.

20.Proby C, Minello A, Quantin C, Jooste V, Binquet C, Hägi M, et al. Chronic viral hepatitis and risk of lymphoid malignancies: a retrospective twelve-year population-based cohort study in Côte d’Or, France. Dig Liver Dis. 2012 Feb;44(2):160–5.

21.Maynadié M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica. 2011 Jan;96(1):55–61.

22.Maynadié M. [Epidemiology of myelodysplastic syndromes]. Rev Prat. 2010 Dec 20;60(10):1410–1.

23.Maynadié M. [Epidemiology of lymphoma]. Rev Prat. 2010 Jan 20;60(1):33–8.

24.Girodon F, Dutrillaux F, Broséus J, Mounier M, Goussot V, Bardonnaud P, et al. Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia. 2010 Apr;24(4):900–3.

25.Girodon F, Bonicelli G, Schaeffer C, Mounier M, Carillo S, Lafon I, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica. 2009 Jun;94(6):865–9.

26.Girodon F, Jooste V, Maynadie M, Favre B, Schaeffer C, Carli P. Incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the Côte d’Or area, France, during 1980-99. J Intern Med. 2005 Jul;258(1):90–1.

27.Cailliod R, Quantin C, Carli PM, Jooste V, Le Teuff G, Binquet C, et al. A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models. Eur J Epidemiol. 2005;20(12):993–1001.

28.Dutrillaux F, Maynadié M, Carli PM. Low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Apr 15;350(16):1683–5; author reply 1683-1685.

29.Maynadié M, Gerland L, Aho S, Girodon F, Bernier M, Brunet C, et al. Clinical value of the quantitative expression of the three epitopes of CD34 in 300 cases of acute myeloid leukemia. Haematologica. 2002 Aug;87(8):795–803.

30.Carli PM, Maynadié M. [Epidemiology and etiology of non-Hodgkin’s lymphoma]. Rev Prat. 2002 May 1;52(9):945–50.

31.Carli PM, Sgro C, Parchin-Geneste N, Isambert N, Mugneret F, Girodon F, et al. Increase therapy-related leukemia secondary to breast cancer. Leukemia. 2000 Jun;14(6):1014–7.

32.Bourdais-Mannone C, Quantin C, Abrahamowicz M, Mannone L, Brunet-Lecomte P, Aho LS, et al. Testing the proportional hazards assumption in medical survival studies–application to a population-based study of acute myeloid leukaemia. J Epidemiol Biostat. 1999;4(2):83–92.

33.Carli PM, Girodon F, Francisco C, Guiguet M, Maynadié M. Epidemiology of monoclonal gammopathy in Cote d’Or, France. Br J Haematol. 1998 May;101(2):390.

34.Carli PM, Coebergh JW, Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978. EUROCARE Working Group. Eur J Cancer. 1998 Dec;34(14 Spec No):2253–63.

35.Rolland-Portal I, Tazi MA, Milan C, Couillault C, Carli PM. Non-Hodgkin’s lymphoma: time trends for incidence and survival in Côte-d’Or, France. Int J Epidemiol. 1997 Oct;26(5):945–52.

36.Maynadié M, Campos L, Moskovtchenko P, Sabido O, Aho S, Lenormand B, et al. Heterogenous expression of CD15 in acute lymphoblastic leukemia: a study of ten anti-CD15 monoclonal antibodies in 158 patients. Leuk Lymphoma. 1997 Mar;25(1–2):135–43.

37.Maynadié M, Verret C, Moskovtchenko P, Mugneret F, Petrella T, Caillot D, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996 Jul;74(2):288–90.

38.Carli PM, Boutron MC, Maynadié M, Bailly F, Caillot D, Petrella T. Increase in the incidence of non-Hodgkin’s lymphomas: evidence for a recent sharp increase in France independent of AIDS. Br J Cancer. 1994 Oct;70(4):713–5.

39.Carli PM. Epidemiology of polycythemia vera in Cte d’Or (Burgundy). Nouv Rev Fr Hematol (1978). 1994 Apr;36(2):147–9.

40.Carli PM. Epidemiology of polycythemia vera in Cte d’Or (Burgundy). Nouv Rev Fr Hematol (1978). 1994 Apr;36(2):147–9.

41.Maynadié M, Bailly F, Casasnovas RO, Coudert B, Carli PM. Immunophenotype in erythroleukemia secondary to myelodysplastic syndrome. Blood. 1992 Aug 15;80(4):1097.

42.Carli PM. Importance of a specialized registry of haematopoietic malignancies. Nouv Rev Fr Hematol (1978). 1991;33(2):119–21.

43.Heudes D, Carli PM, Bailly F, Milan C, Mugneret F, Petrella T. Myeloproliferative disorders in the department of Côte d’Or between 1980 and 1986. Nouv Rev Fr Hematol (1978). 1989;31(5):375–8.

44.Carli PM, Bailly F, Tavernier C, Milan C, Heudes D, Lavault JF. Multiple myeloma: epidemiological features in a well-defined population in Burgundy, France. Int J Epidemiol. 1989 Jun;18(2):330–3.

45.Devilliers E, Carli PM, Lorenzini JL, Mugneret F, Turc-Carel C, Bonhomme J, et al. [Acute myeloid leukemia in chronic lymphoid leukemia treated with chlorambucil]. Presse Med. 1986 Oct 18;15(36):1832.

46.Carli PM, Milan C, Lorenzini JL, Guy H, Michiels R. Incidence of hematopoietic malignancies in a well-defined population in France. Oncology. 1986;43(6):354–7.

47.Carli PM, Milan C, Lange A, Devilliers E, Guy H, Faivre J. Haematopoietic malignancies in Côte d’Or (France): a population based study. Br J Cancer. 1986 Jun;53(6):811–5.

48.Carli PM, Milan C, Bordes M, Bonhomme J. [Incidence of chronic lymphocytic leukemia in the Department of Côte-d’Or]. Nouv Rev Fr Hematol (1978). 1986;28(1):23–6.

49.Carli PM. Chronic lymphocytic leukaemia: an unexpected high incidence rate in Burgundy (France)? Int J Epidemiol. 1986 Jun;15(2):278.

50.Carli PM, Milan C, Lorenzini JL, Devilliers E, Turc C, Cortet P, et al. [Establishing a registry of malignant hemopathies in Côte-d’Or. Preliminary results]. Nouv Rev Fr Hematol (1978). 1983;25(5):329–35.